Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GEP signatures in tumors from women with high grade early breast cancer

ABSTRACT: GEP signatures in tumors from women with high grade early breast cancer

PROVIDER: PRJNA614941 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

GEP signatures in tumors from women with high grade early breast cancer [PrimitiveTumor].

Project description:GEP signatures in tumors from women with high grade early breast cancer [PrimitiveTumor].

| PRJNA614942 | ENA

GEP signatures in tumors from women with high grade early breast cancer [PrimitiveTumor].

Project description:Several molecular signatures are able to predict the activity of adjuvant chemotherapy in breast cancer patients. However, no molecular data are already available to detect microenvironment molecular signature that can identify patients who are good candidates for treatment with immune checkpoint inhibitors (ICIs). For this reason, in a series of women with operable high grade breast cancer (HGBC), we tried to combine the ECM3 and IFN molecular signatures reflecting different aspects of tumor microenvironment that can better draw the picture of the tumor microenvironment in which the immune cells are in close contact with extracellular matrix. Grade 3 primary tumors

2020-12-23 | GSE147471 | GEO

GEP signatures in tumors from women with high grade early breast cancer

2020-12-23 | GSE147472 | GEO

microRNA profiling in different grading of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Project description:Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and heterogeneous tumors presenting a wide spectrum of different clinical and biological characteristics. In these tumors, the histological evaluation is a crucial element of clinical management. Currently, tumor grading, determined by Ki-67 staining and mitotic counts, is the most reliable predictor of prognosis. This scoring method is time-consuming and a high reproducibility cannot be achieved. Novel approaches are needed to support histological evaluation and prognosis. In this study, starting from a microarray analysis, we defined the miRNAs signature for poorly differentiated NETs (G3) compared to well differentiated NETs (G1 and G2) consisting of 56 deregulated miRNAs. Moreover, we identified 8 miRNAs that were expressed in all GEP-NETs grades but at different level. Among these miRNAs, we found miR-96-5p that raised its expression levels from grade 1 to grade 3; inversely, its target FOXO1 was decrease from grade 1 to grade 3. Our results reveal that the miRNAs expression profile of GEP-NET correlates their expression with grading showing a potential advantage of miRNA quantification to aid clinicians in the classification of common GEP-NETs subtypes.

2020-08-04 | GSE135034 | GEO

GEP signatures of primary breast cells radiation treated.

Project description:GEP signatures of primary breast cells radiation treated.

| PRJNA435496 | ENA

CD34mono GEP

Project description:CD34mono GEP

| PRJNA521169 | ENA

Expression profile of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NET)

Project description:Expression profile of human GEP-NET tumors, including 113 fresh frozen biopsies of primary and metastatic tumours originating from pancreas (P-NET, 83 primary and 30 metastasis), 81 from small intestine (SI-NET, 44 primary and 37 metastasis), and 18 from rectum (RE-NET, 3 primary and 15 metastasis).

2018-02-25 | GSE98894 | GEO

microRNA profiling in different grading of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Project description:microRNA profiling in different grading of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

| PRJNA557200 | ENA

Transcription profiling of human grade II astrocytic tumor (astrocytomas) vs grade IV tumors (glioblastoma)

Project description:Comparison of grade II astrocytic tumor (astrocytomas) with grade IV tumors (glioblastoma)

2007-03-01 | E-MEXP-567 | biostudies-arrayexpress

Can High Grade Serous Ovarian Cancer TCGA Gene Expression Signatures be seen in High Grade Endometrioid or Clear Cell Ovarian Cancer?

Project description:The goal of the study was to examine the transcriptional profile of ovarian cancer cancers in order to develop validated clinically useful prognostic signatures with the potential to guide therapy decisions. Fresh frozen samples were prospectively collected from a series of 107 consecutive women with high-grade serous ovarian, primary peritonial, or fallopian tube cancer as well as high grade clear cell and endometrioid cancer who underwent surgery by a gynecologic oncologist at Mayo Clinic between 1994 and 2005. All patients received postoperative chemotherapy with a platinum agent, and 75% received a taxane. All patients signed an Institutional Review Board approved consent for bio-banking, clinical data extraction and molecular analysis. Median follow-up time was 35 months (range, 1-202 months). Fourteen patients (8%) were included in the TCGA study.

2015-10-01 | GSE73614 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data